Enobosarm is categorized as non-steroidal selective androgen receptor modulator and restricted exclusively to preclinical pharmacological laboratory research, not approved for human clinical medication, dietary supplement production or direct oral consumption globally. It features tissue-selective androgen receptor binding capacity to activate anabolic responses in skeletal muscle and bone tissues while exerting minimal stimulatory impact on prostate tissue compared with traditional synthetic anabolic steroids. Primary research directions include in-vivo animal experiments targeting age-induced sarcopenia and disease-associated cachexia; researchers adopt aged rodents and tumor-bearing animal models to investigate its capability to increase lean muscle mass, inhibit muscular atrophy and reverse progressive body weight loss caused by malignant disorders and chronic wasting illnesses. It is also frequently utilized in osteoporosis pharmacodynamic screening trials to assess its efficacy for elevating bone mineral density and suppressing abnormal bone resorption without typical androgen-related prostate hyperplasia risks. At cellular research level, this compound works as a tool reagent to explore androgen receptor downstream signaling pathways and facilitate structural optimization of novel anti-wasting therapeutic candidates. Classified as prohibited doping substance by international anti-doping authorities, any unauthorized human administration for bodybuilding or sports performance enhancement violates pharmaceutical control rules across most countries.
GHS hazard falls under Warning category with H315 skin irritant and H319 serious eye irritation hazard statements, standardized full personal protective equipment must be equipped throughout all lab handling procedures. Experiment operators need nitrile protective gloves, splash-proof safety goggles and dustproof lab coat during powder weighing and stock solution preparation to prevent inhalation of fine dust particles, prolonged skin contact and unintended accidental ingestion. All leftover solid residues and waste organic solvents containing this SARM compound shall be classified as hazardous chemical waste and submitted to licensed professional disposal institutions per local environmental legislations rather than ordinary domestic trash disposal. Existing preclinical animal toxicology findings indicate sustained high-dose exposure leads to suppressed endogenous testosterone synthesis, triggering endocrine imbalance, fatigue and declined sexual desire among tested animals. Long-term repeated administration may impose mild metabolic burden on liver and potential hidden cardiovascular risks, whereas comprehensive long-term carcinogenicity and complete reproductive toxicity test data remain incomplete currently. Test substance dosing is strictly banned for all pregnant animal experimental groups due to undefined developmental toxic hazards. Store separately from strong oxidants and concentrated mineral acids to prevent undesired chemical decomposition and purity decline during long-term warehouse preservation.
